Trial Profile

An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-402257 Administered Orally to Patients With Advanced Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Luvixasertib (Primary) ; Fulvestrant
Indications Advanced breast cancer; Gastrointestinal cancer; HER2 negative breast cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man

Most Recent Events

09 Dec 2022 According to Treadwell Therapeutics media release, results from this trial were presented at the 2022 San Antonio Breast Cancer Symposium (SABCS) 2022.
09 Dec 2022 Results published in the Treadwell Therapeutics Media Release.
21 Nov 2022 According to Treadwell Therapeutics media release, data from this study have been accepted for presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com